Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Urologiia ; (4): 74-6, 78-9, 2013.
Artigo em Russo | MEDLINE | ID: mdl-24159771

RESUMO

Results of use of UroBeam laser diode in 72 patients with benign prostatic hyperplasia (BPH) were analyzed. Average prostate volume was 67.29 +/- 26.72 cm3, the duration of vaporization--69.2 +/- 23.7 min. Blood loss was minimal. In the period from 2 weeks to 4 months after surgery, 9 patients have developed acute urinary retention. In the early postoperative period, acute prostatitis was diagnosed in 7 patients and was jugulated using drug treatment. The laser vaporization of BPH led to a three-fold reduction in the severity of urinary disorders and increase the urinary flow rate. The combination of laser vaporization of the prostate with transurethral resection of the prostate allow to improve the recovery of urination after surgery.


Assuntos
Terapia a Laser/métodos , Hiperplasia Prostática/cirurgia , Idoso , Idoso de 80 Anos ou mais , Humanos , Calicreínas/sangue , Terapia a Laser/efeitos adversos , Terapia a Laser/instrumentação , Lasers Semicondutores , Masculino , Pessoa de Meia-Idade , Antígeno Prostático Específico/sangue , Hiperplasia Prostática/diagnóstico , Ressecção Transuretral da Próstata/métodos , Resultado do Tratamento , Retenção Urinária/etiologia
2.
Urologiia ; (6): 55-8, 2010.
Artigo em Russo | MEDLINE | ID: mdl-21427997

RESUMO

The efficacy of indigal plus containing indol-3-carbinol, epigallocatexin-3-gallat and Serenoa repens extract in combination with sparfloxacin was studied in a trial with participation of 30 patients with chronic infectious prostatitis associated with intracellular agents. Group 1 (n=15) received indigal plus (2 capsules twice a day for 3 months) and sparfloxacin (200 mg twice a day for 1 month). Group 2 including 15 matched controls received sparfloxacin alone according to the same schedule. The examination included questionnaire survey (IPSS, QoL, NIH-CPSI), blood count, urinalysis, PSA test, microscopy, bacteriological study of prostatic secretion, uroflowmetry, transrectal ultrasound investigation of the prostate with residual urine assay, laser doppleroflowmetry. The examinations were performed on the treatment day 30, 60 and 90. After the antibacterial treatment chlamidia, ureaplasma and E.coli were detected in 13.3, 6.7 and 26.7% patients of the control group, in 6.7, 6.7 and 6.7% patients of the study group, respectively. Thus, the addition of a pathogenetic drug indigal plus to sparfloxacin treatment promoted normalization of apoptosis of the infected cells, led to more effective bacterial eradication, enhanced regression of the symptoms. It is recommended to include indigal plus in a basic scheme of treatment of patients with chronic infectious prostatitis.


Assuntos
Infecções Bacterianas/tratamento farmacológico , Próstata/efeitos dos fármacos , Prostatite/tratamento farmacológico , Doenças Bacterianas Sexualmente Transmissíveis/tratamento farmacológico , Adulto , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Apoptose/efeitos dos fármacos , Infecções Bacterianas/microbiologia , Infecções Bacterianas/patologia , Catequina/análogos & derivados , Catequina/uso terapêutico , Doença Crônica , Combinação de Medicamentos , Quimioterapia Combinada , Fluoroquinolonas/administração & dosagem , Fluoroquinolonas/uso terapêutico , Humanos , Indóis/uso terapêutico , Masculino , Pessoa de Meia-Idade , Extratos Vegetais/uso terapêutico , Próstata/diagnóstico por imagem , Próstata/microbiologia , Próstata/patologia , Prostatite/microbiologia , Prostatite/patologia , Doenças Bacterianas Sexualmente Transmissíveis/microbiologia , Doenças Bacterianas Sexualmente Transmissíveis/patologia , Inquéritos e Questionários , Resultado do Tratamento , Ultrassonografia , Urodinâmica/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA